Who we are
Cognito Therapeutics is advancing the field of neuromodulation to create novel therapeutics that improve the lives of patients living with neurodegenerative diseases.
At a glance
Our company by the numbers
50,129,284
Patients with neurodegenerative diseases
42
Employees living and working across the world
58%
Improvement in memory functions for clinical trial patients
2016
Year we were officially founded
Meet the team
You?
Recognized and proud
Latest news and updates
Stay up to date
Oct 30, 2023
Neuromod tech developer Cognito Therapeutics has a new CCO
Oct 27, 2023
Clinical Potential of Cognito’s Gamma Sensory Stimulation Device in Alzheimer Disease: Brett Vaughan
May 9, 2023
Neuroimmune Interactions: From Basic Mechanisms to Novel Therapeutic Directions
Apr 17, 2023